Skip to main content

Nuvation Bio, Inc. (NUVB)

NYSE: NUVB · Delayed Price · USD
9.25 -0.22 (-2.32%)
Sep 22, 2021 4:00 PM EDT - Market closed
Market Cap2.06B
Revenue (ttm)n/a
Net Income (ttm)-49.21M
Shares Out216.76M
EPS (ttm)-0.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume337,343
Open9.55
Previous Close9.47
Day's Range9.24 - 9.57
52-Week Range7.66 - 15.23
Betan/a
Analystsn/a
Price Target18.20 (+96.8%)
Est. Earnings DateOct 28, 2021

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PAR...

IndustryBiotechnology
Founded2018
Employees51
Stock ExchangeNYSE
Ticker SymbolNUVB
Full Company Profile

Financial Performance

Financial Statements

News

Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...

1 month ago - PRNewsWire

Nuvation Bio Appoints David C. Hanley, Ph.D.

NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...

3 months ago - PRNewsWire

Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference

NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...

3 months ago - PRNewsWire

David Abrams Buys 3 Stocks in 1st Quarter

David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, disclosed his first-quarter portfolio earlier this month.

Other symbols:CCOCHNGCTLPPCGSCUTMDX
4 months ago - GuruFocus

Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update

NEW YORK, May 17, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...

4 months ago - PRNewsWire

Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering

SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,...

Other symbols:PANA
5 months ago - GlobeNewsWire

Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio

SAN FRANCISCO--(BUSINESS WIRE)--Panacea Acquisition Corp., a Delaware corporation (the “Company”) (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333...

Other symbols:PANA
8 months ago - Business Wire

4 SPAC Mergers: What The KBLM, ACAM, PANA And SMMC Deals Mean For Investors

Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: P...

Other symbols:ACAMPANA
10 months ago - Benzinga